Department of Critical Care Medicine, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Eur Rev Med Pharmacol Sci. 2024 Mar;28(6):2483-2492. doi: 10.26355/eurrev_202403_35755.
The stability of hemodynamics plays a vital role in the process of anesthesia induction for patients with septic shock. As a new-type benzodiazepine, remimazolam has numerous advantages, including rapid induction, rapid recovery, stable hemodynamics, and mild respiratory depression. Nevertheless, reports about the effects of remimazolam on hemodynamics in patients with septic shock are still limited. The study aimed to evaluate the effects that different doses of remimazolam have on hemodynamics in inducing general anesthesia in patients with septic shock.
Admitted to the intensive care unit of our hospital from January 2023 to June 2023, 75 patients with septic shock caused by acute appendicitis-induced sepsis were selected as observation subjects. They were randomly assigned to receive low-dose [0.2 mg/(kg·h)], medium-dose [0.3 mg/(kg·h)], and high-dose [0.4 mg/(kg·h)] remimazolam by using a random number table, with 25 patients in each group. Their intraoperative conditions were recorded, including operation duration, intraoperative hemorrhage volume, intraoperative transfusion volume, and decannulation time. Hemodynamic parameters, including mean arterial pressure (MAP), heart rate (HR), cardiac index (CI), and stoke volume index (SVI) were collected at seven-time points (T0: before induction; T1: before intubation; T2: after intubation; T3: the start of operation; T4: 15 min after operation; T5: 30 min after operation; T6: the end of operation). We also compared hepatic and renal function indexes, including blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin (PCT), white blood cells (WBC), tumor necrosis factor-α2 (TNF-α2), and Interleukin-6 (IL-6), of the three groups of patients before operation and 1, 3, 5, 7 days after operation. In addition, the incidence of adverse reactions in the three groups was recorded and compared.
During remimazolam induction, the number of patients with intraoperative need for rescue remimazolam in the medium-dose and high-dose groups was significantly lower than in the low-dose group (p < 0.05). In terms of hemodynamic indexes, MAP in the high-dose group at T2 was lower than that at T0 (p < 0.05), and MAP at T2 was significantly lower in the high-dose group than that in the medium-dose group (p < 0.05). Furthermore, MAP at T4 in the medium-dose and high-dose groups declined compared with the low-dose group (p < 0.05). There were no significant differences in HR, CI, and SVI at different time points among the three groups (p > 0.05), but levels of HR and SVI decreased and CI increased after anesthesia compared with those before operation. Additionally, in comparison with the levels before operation, levels of sCR, BUN, PCT, WBC, TNF-α, and IL-6 were higher on postoperative days 1, 3 (p < 0.05) and lower on postoperative day 7 (p < 0.05). After the operation, both levels of BUN and sCR in the medium-dose and high-dose groups were lower than those in the low-dose group (p < 0.05).
Remimazolam is safe and effective for inducing general anesthesia in patients with septic shock. Low, medium, and high doses of remimazolam can maintain a stable hemodynamic state, and the recovery of hepatic and renal function is certain to depend on the dose.
血流动力学的稳定在脓毒性休克患者的麻醉诱导过程中起着至关重要的作用。作为一种新型苯二氮䓬类药物,瑞马唑仑具有诱导迅速、恢复迅速、血流动力学稳定、呼吸抑制轻微等诸多优点。然而,关于瑞马唑仑对脓毒性休克患者血流动力学影响的报道仍然有限。本研究旨在评估不同剂量瑞马唑仑对脓毒性休克患者全麻诱导时血流动力学的影响。
选择 2023 年 1 月至 2023 年 6 月我院重症监护病房收治的因急性阑尾炎所致脓毒症引起的脓毒性休克患者 75 例为观察对象。采用随机数字表法将其随机分为低剂量[0.2mg/(kg·h)]、中剂量[0.3mg/(kg·h)]和高剂量[0.4mg/(kg·h)]瑞马唑仑组,每组 25 例。记录术中情况,包括手术时间、术中出血量、术中输血量和拔管时间。分别于七个时间点(T0:诱导前;T1:插管前;T2:插管后;T3:手术开始时;T4:手术后 15min;T5:手术后 30min;T6:手术结束时)采集血流动力学参数,包括平均动脉压(MAP)、心率(HR)、心指数(CI)和每搏量指数(SVI)。比较三组患者术前及术后 1、3、5、7d的肝肾功能指标,包括血尿素氮(BUN)、血清肌酐(sCr)、降钙素原(PCT)、白细胞(WBC)、肿瘤坏死因子-α2(TNF-α2)和白细胞介素-6(IL-6)。记录三组患者不良反应的发生情况并进行比较。
瑞马唑仑诱导过程中,中、高剂量组术中需要抢救性使用瑞马唑仑的患者数量明显少于低剂量组(p<0.05)。在血流动力学指标方面,高剂量组 T2时的 MAP 低于 T0(p<0.05),且高剂量组 T2时的 MAP 明显低于中剂量组(p<0.05)。此外,中、高剂量组 T4时的 MAP 低于低剂量组(p<0.05)。三组患者不同时间点的 HR、CI 和 SVI 无明显差异(p>0.05),但麻醉后 HR 和 SVI 水平下降,CI 水平升高。与术前相比,三组患者术后 1、3d 的 sCR、BUN、PCT、WBC、TNF-α和 IL-6 水平均升高(p<0.05),术后 7d 时均降低(p<0.05)。术后,中、高剂量组的 BUN 和 sCR 水平均低于低剂量组(p<0.05)。
瑞马唑仑用于脓毒性休克患者全麻诱导安全有效。低、中、高剂量的瑞马唑仑均可维持稳定的血流动力学状态,且肝肾功能的恢复一定程度上取决于剂量。